Quince Therapeutics Hosts KOL Event on PH-ILD and BOS Treatments

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 /CourierPR/ -- Quince Therapeutics, a clinical-stage biopharmaceutical company, is set to host a virtual event on September 28, 2026, to discuss the current treatment landscape for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). The event, which will run from 12:30 to 2:00 PM Eastern Time, will feature key opinion leaders (KOLs) from leading medical institutions, including Aaron B. Waxman, MD, PhD, from Brigham and Women's Hospital; Paul Yu, MD, PhD, from Massachusetts General Hospital; and Steven Hays, MD, from UCSF Health.

The KOLs will delve into the unmet medical needs associated with PH-ILD and BOS, as well as the potential role of LAM-001, an investigational once-daily inhaled formulation of rapamycin, as a new therapeutic option. LAM-001 is currently in Phase 2 clinical trials for both conditions and is designed to inhibit the mTOR pathway, which has been shown to play a significant role in the progression of these diseases.

Dr. Waxman, a director of the Pulmonary Vascular Disease Program at Brigham and Women's Hospital, will discuss the potential of mTOR inhibition as a disease-modifying mechanism. Dr. Yu, a physician-scientist and director of the Cardiovascular Research Center at Massachusetts General Hospital, will explore the unique advantages of delivering rapamycin through an inhaled route. Dr. Hays, the medical director of the UCSF Advanced Lung Disease and Lung Transplant Program, will provide insights into the current treatment landscape and the emerging therapies for BOS.

LAM-001, a proprietary inhaled formulation of rapamycin, is being studied for its potential to address the underlying mechanisms of PH-ILD and BOS. The company has already presented compelling Phase 2a data from a trial in pulmonary hypertension, which showed improvements in exercise capacity, pulmonary hemodynamics, and lung function. Based on these results, Quince Therapeutics has advanced LAM-001 into Phase 2b trials for PH-ILD and a Phase 2 trial for BOS.

According to the press release, the event will include a live question and answer session, providing attendees with the opportunity to engage directly with the KOLs. The discussion will cover the design and objectives of the ongoing clinical trials, as well as the potential benefits of LAM-001 for patients with PH-ILD and BOS.

Quince Therapeutics is committed to developing novel, disease-modifying therapies for serious, underserved diseases. The company is currently conducting Phase 2b trials for PH-ILD and a Phase 2 trial for BOS, with data expected in the first quarter of 2027 and 2028, respectively. Additionally, the company plans to initiate a Phase 2 study for LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH) in late 2026.

The event is aimed at providing a comprehensive overview of the current treatment landscape and the potential of LAM-001 as a new therapeutic option for patients with PH-ILD and BOS. Attendees will gain valuable insights into the latest research and clinical developments in these conditions, as well as the potential benefits of LAM-001.